Abstract
Purpose
To determine long-term outcomes of a cohort of children with germinoma treated with chemotherapy and radiation therapy without primary tumor boost even in the absence of complete response to chemotherapy
Methods
This retrospective study analyzed the outcome of patients with germinoma consecutively diagnosed and treated at a tertiary care center from January 2000 to December 2021. MRIs were reviewed by two radiologists, blinded to patient data. Tumor location at diagnosis, tumor response to chemotherapy and at completion of radiation therapy and site of relapse were assessed. Tumor response was assessed radiologically by determining the tumor size and response on diffusion-weighted imaging, in addition to biochemical, cytological parameters and neurological status.
Results
Of 46 pediatric germinoma patients, 29 children (14 male; median age 12.8 years) received no primary tumor boost. Median follow-up was 63 months (range 9–187 months). Twenty-five children had localized disease and tumor location was suprasellar (n = 11), pineal (n = 10), bifocal (n = 3) and basal ganglia (n = 1) while 4 children had metastatic disease at presentation. All patients completed multi-agent chemotherapy followed by either ventricular irradiation (VI) (23.4 Gy) (n = 23), whole brain (WBI) (23.4 Gy) (n = 5) or craniospinal radiation (CSI) (23.4 Gy) (n = 1). Two children, who had localized disease at presentation and received VI after chemotherapy, relapsed 9 months and 32 months after completion of treatment respectively. No patient had a local relapse. Location of relapse was distant, outside (n = 1) and out- and inside (n = 1) the irradiation field. Five-year progression free survival (PFS) was 91% and overall survival (OS) was 100%.
Conclusions
In this case series, excellent 5-year PFS and OS rates were achieved with chemotherapy followed by radiation therapy of 23.4 Gy delivered without primary tumor boost. No local relapse was observed despite omitting primary tumor boost in patients with localized and metastatic germinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bamberg M, Kortmann RD, Calaminus G, Becker G, Meisner C, Harms D, Göbel U (1999) Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 8:2585–2592. https://doi.org/10.1200/JCO.1999.17.8.2585
Matsutani M (2005) Treatment for intracranial germinoma: Final results of the Japanese study group neuro-oncology; abstracts for the second international symposium on central nervous system germ cell tumors: November 18–21, 2005, Los Angeles. California. Neuro Oncol. 4:513–533. https://doi.org/10.1215/S1152851705200406
Alapetite C, Brisse H, Patte C, Raquin MA, Gaboriaud G, Carrie C, Habrand JL, Thiesse P, Cuilliere JC, Bernier V, Ben-Hassel M, Frappaz D, Baranzelli MC, Bouffet E (2010) Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro Oncol 12:1318–1325. https://doi.org/10.1093/neuonc/noq093
Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garrè ML, Patte C, Ricardi U, Saran F, Frappaz D (2013) Calaminus G, Kortmann R, Worch J, Nicholson JC, Alapetite C, Garrè ML, Patte C, Ricardi U, Saran F, Frappaz D (2013) SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 6:788–796. https://doi.org/10.1093/neuonc/not019
Bartels U, Onar-Thomas A, Patel SK, Shaw D, Fangusaro J, Dhall G, Souweidane M, Bhatia A, Embry L, Trask CL, Murphy ES, MacDonald S, Wu S, Boyett JM, Leary S, Fouladi M, Gajjar A, Khatua S (2021) Phase II trial of response-based radiation therapy for patients with localized germinoma: a children’s oncology group study. Neuro Oncol 24(6):974–983. https://doi.org/10.1093/neuonc/noab270
Calaminus G, Bison B, Faure-Conter C, Frappaz D, Peyrl A, Gerber N, Müller JE, Thankamma A, Mitra D, Cross J, Pietsch T, Smith C, Solem K, Devenney I, Garre ML, Brisse H, Zimmermann M, Kortmann RD, Alapetite C, Nicholson J (2020) 24Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy- early results of the SIOP CNS GCT II Study. Neuro Oncol 22(suppl3):iii343–iii344. https://doi.org/10.1093/neuonc/noaa222.292
Cheng S, Kilday JP, Laperriere N, Janzen L, Drake J, Bouffet E, Bartels U (2016) Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. J Neurooncol 127(1):173–180. https://doi.org/10.1007/s11060-015-2029-1
Morana G, Shaw D, MacDonald SM, Alapetite C, Ajithkumar T, Bhatia A, Brisse H, Jaimes C, Czech T, Dhall G, Fangusaro J, Faure-Conter C, Fouladi M, Hargrave D, Harreld JH, Mitra D, Nicholson JC, Souweidane M, Timmermann B, Calaminus G, Bartels U, Bison B, Murray MJ (2022) Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European society for paediatric oncology brain tumour group and north american children’s oncology group. Lancet Oncol 23(5):e218–e228. https://doi.org/10.1016/S1470-2045(22)00063-8
Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC (2015) Consensus on the management of intracranial germ-cell tumours. Lancet Oncol 16(9):e470–e477. https://doi.org/10.1016/S1470-2045(15)00244-2
da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J (2010) Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 54(3):377–383. https://doi.org/10.1002/pbc.22381
Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL (1996) Chemotherapy without irradiation–a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The first international central nervous system germ cell tumor study. J Clin Oncol 14(11):2908–2915. https://doi.org/10.1200/JCO.1996.14.11.2908
Mabbott DJ, Monsalves E, Spiegler BJ, Bartels U, Janzen L, Guger S, Laperriere N, Andrews N (2011) Bouffet E (2011) Longitudinal evaluation of neurocognitive function after treatment for central nervous system germ cell tumors in childhood. Cancer 117(23):5402–5411. https://doi.org/10.1002/cncr.26127. (Epub May 11)
Wilkening GN, Madden JR, Barton VN, Roberts A, Foreman NK (2011) Memory deficits in patients with pediatric CNS germ cell tumors. Pediatr Blood Cancer 57(3):486–491. https://doi.org/10.1002/pbc.23096
Mak DY, Siddiqui Z, Liu ZA, Dama H, MacDonald SM, Wu S, Murphy ES, Hall MD, Malkov V, Onar-Thomas A, Ahmed S, Dhall G (2022) Tsang DS (2022) Photon versus proton whole ventricular radiotherapy for non-germinomatous germ cell tumors: a report from the children’s oncology group. Pediatr Blood Cancer 69(9):e29697. https://doi.org/10.1002/pbc.29697
Villani A, Bouffet E, Blaser S, Millar BA, Hawkins C, Bartels U (2008) Inherent diagnostic and treatment challenges in germinoma of the basal ganglia: a case report and review of the literature. J Neurooncol 88(3):309–314. https://doi.org/10.1007/s11060-008-9568-7
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
The following authors listed in the manuscript have contributed significantly to the experimental design (J.C.F., I.Y.B., U.B.) and its implementation (O.M., B.E., T.M., E. B., D.S.T., N.L., P.D., J.D). All authors have been involved in the analysis and interpretation of the data, writing of the manuscript at the draft and any revision stages, and have read and approved the final version.
Corresponding author
Ethics declarations
Conflict of interest
The authors have not disclosed any competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Foo, J.C., Yaman Bajin, I., Marushchak, O. et al. Time to dismiss boost? Outcomes of children with localized and metastatic germinoma. J Neurooncol 162, 443–448 (2023). https://doi.org/10.1007/s11060-023-04307-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-023-04307-5